GlassScriptPhysician profile
Weston S Carter
NPI 1316385198
$2,849.26
in general payments reported to CMS, 2019-2025
30 companies · $1,135 in 2025
The $1,135 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.56 · 2021: $23.12 · 2022: $12.31 · 2023: $700 · 2024: $954 · 2025: $1,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,789.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $338.35 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $288.78 | 2023-2025 | |
| Glaxosmithkline, LLC. | $219.61 | 2023-2025 | Trelegy Ellipta, Penmenvy |
| Lilly USA, LLC | $211.81 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $193.89 | 2021-2025 | Farxiga, Airsupra, Fasenra |
| Novo Nordisk INC | $186.14 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.18 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $138.43 | 2023-2025 | |
| Corium, LLC | $123.17 | 2023-2025 | Azstarys |
| Astellas Pharma US INC | $93.39 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $88.44 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $73.62 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $68.49 | 2023-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $62.01 | 2023-2025 | Rexulti |
| Amgen INC. | $61.38 | 2023-2025 | Repatha, Otezla, Repatha |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $59.97 | 2024-2025 | Trintellix |
| Lundbeck LLC | $52.78 | 2023-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $48.02 | 2023-2025 | Qelbree, Qelbree |
| Inspire Medical Systems, INC. | $40.26 | 2024 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.98 | 2025 | Caplyta |
| Viatris Specialty LLC | $38.67 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $33.19 | 2023 | |
| Mylan Specialty L.P. | $32.88 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $31.33 | 2024-2025 | Vaxelis, Capvaxive, Gardasil 9 |
| Harmony Biosciences LLC | $29.71 | 2024 | |
| Sumitomo Pharma America, INC. | $26.08 | 2023 | Gemtesa |
| Axsome Therapeutics, INC. | $25.12 | 2025 | Auvelity |
| Sanofi Pasteur INC. | $24.56 | 2019 | |
| Grifols USA, LLC | $22.03 | 2023 | Prolastin-C Liquid |
| Seqirus USA INC | $18.99 | 2024 | Fluad, Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weston Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.